ONCOCROSS

  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

CONTACT US
  • KR
  • EN
  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

  • KR
  • EN
CONTACT US
  • Main
  • News/IR
  • Press Releases

메디칼타임즈

국내 약가인하·미 관세 이슈 겹친 제약바이오 "해외진출이 답"

  • 01-29-2026
https://www.medicaltimes.com/Main/News/NewsView.html?ID=1167064
Previous
온코크로스, AI 플랫폼 발굴 항암 파이프라인 'OC-212e' 美 특허 등록 02-10-2026
Next
온코크로스, 단백체 분석 기업 '오믹스AI' 투자 01-08-2026
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
Room 905, 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, Korea (Munjeong-dong, Munjeong Hyundai Knowledge Industry Center 1-2)
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.